Early and persistent intraventricular conduction abnormalities and requirements for pacemaking after percutaneous replacement of the aortic valve.

Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11

Transcatheter aortic valve implantation: current and future approaches. Nat Rev Cardiol (2011) 1.22

Surface and intracardiac ECG for discriminating conduction disorders after CoreValve implantation. Clin Res Cardiol (2011) 1.02

Imaging to select and guide transcatheter aortic valve implantation. Eur Heart J (2014) 1.01

Clinical impact of a new left bundle branch block following TAVI implantation: 1-year results of the TAVIK cohort. Clin Res Cardiol (2014) 0.97

Transcatheter aortic valve replacement: design, clinical application, and future challenges. Yale J Biol Med (2012) 0.88

Incidence rate and predictors of permanent pacemaker implantation after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis. J Interv Card Electrophysiol (2011) 0.84

New conduction abnormalities after TAVI--frequency and causes. Nat Rev Cardiol (2012) 0.83

Patient selection for transcatheter aortic valve implantation: An interventional cardiology perspective. Ann Cardiothorac Surg (2012) 0.82

Predictive factors for pacemaker requirement after transcatheter aortic valve implantation. BMC Cardiovasc Disord (2012) 0.81

Transcatheter aortic valve implantation. Surg Today (2014) 0.80

Transcatheter versus surgical aortic valve replacement: a systematic review and meta-analysis of randomised and non-randomised trials. Open Heart (2014) 0.79

Emerging approaches of transcatheter valve repair/insertion. Cardiol Res Pract (2010) 0.78

Transcatheter resection of the native aortic valve prior to endovalve implantation - A rational approach to reduce TAVI-induced complications. Ann Cardiothorac Surg (2012) 0.77

Impact of left ventricular conduction defect with or without need for permanent right ventricular pacing on functional and clinical recovery after TAVR. Clin Res Cardiol (2015) 0.76

Clinical significance of conduction disturbances after aortic valve intervention: current evidence. Clin Res Cardiol (2014) 0.76

Comparison of multicenter registries and randomized control trials for transcatheter aortic valve replacement (TAVR). Indian Heart J (2013) 0.76

Transcatheter aortic valve implantation: our experience and review of the literature. Balkan Med J (2012) 0.75

Mechanisms of Heart Block after Transcatheter Aortic Valve Replacement - Cardiac Anatomy, Clinical Predictors and Mechanical Factors that Contribute to Permanent Pacemaker Implantation. Arrhythm Electrophysiol Rev (2015) 0.75

Two-dimensional transesophageal echocardiography for aortic annular sizing in patients undergoing transcatheter aortic valve implantation. BMC Cardiovasc Disord (2015) 0.75

Transcatheter aortic valve implantation in 2015. J Geriatr Cardiol (2016) 0.75

Preliminary feasibility and hemodynamic performance of a newly-developed self-expanding bioprosthesis and 16-F delivery system in transcatheter aortic valve implantation in sheep. J Biomed Res (2012) 0.75

Conduction disturbances after transcatheter aortic valve implantation procedures - predictors and management. Postepy Kardiol Interwencyjnej (2016) 0.75

Ongoing requirement for pacing post-transcatheter aortic valve implantation and surgical aortic valve replacement. Interact Cardiovasc Thorac Surg (2013) 0.75

The value of electrophysiologic study in decision-making regarding the need for pacemaker implantation after TAVI. J Interv Card Electrophysiol (2016) 0.75

Transient and persistent conduction abnormalities following transcatheter aortic valve replacement with the Edwards-Sapien prosthesis: a comparison between antegrade vs. retrograde approaches. J Interv Card Electrophysiol (2016) 0.75

Procedural Characteristics and Outcomes of Transcatheter Aortic Valve Implantation: A Single-Center Experience of the First 100 Inoperable or High Surgical Risk Patients with Severe Aortic Stenosis. Acta Cardiol Sin (2017) 0.75

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84

A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 5.94

Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol (2005) 5.63

The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention (2005) 5.16

High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68

Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet (2013) 4.34

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94

A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (2009) 3.55

Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47

Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet (2013) 3.41

Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37

Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12

Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J (2009) 3.06

Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 3.01

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 2.91

Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 2.90

New insights into pacemaker activity: promoting understanding of sick sinus syndrome. Circulation (2007) 2.89

Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation (2013) 2.88

Stent thrombosis. J Am Coll Cardiol (2010) 2.86

Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85

Comprehensive assessment of coronary artery stenoses: computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. J Am Coll Cardiol (2008) 2.81

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet (2011) 2.67

Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med (2011) 2.65

Molecular architecture of the human sinus node: insights into the function of the cardiac pacemaker. Circulation (2009) 2.58

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet (2008) 2.57

Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol (2003) 2.56

Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet (2011) 2.54

Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation (2010) 2.54

Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol (2007) 2.50

Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J (2012) 2.43

Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J (2005) 2.40

Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation (2010) 2.40

Feasibility of combined use of intravascular ultrasound radiofrequency data analysis and optical coherence tomography for detecting thin-cap fibroatheroma. Eur Heart J (2008) 2.36

Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv (2013) 2.32

Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation (2003) 2.31

Assessment of the aortic annulus by multislice computed tomography, contrast aortography, and trans-thoracic echocardiography in patients referred for transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2011) 2.30

Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol (2010) 2.24

Assessment of the SYNTAX score in the Syntax study. EuroIntervention (2009) 2.24

Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation (2011) 2.20

Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation (2011) 2.17

Coronary collaterals: an important and underexposed aspect of coronary artery disease. Circulation (2003) 2.17

Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation (2012) 2.17

Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet (2012) 2.14

Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv (2004) 2.12

Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation (2013) 2.11

Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11

Nomenclature for congenital and paediatric cardiac disease: historical perspectives and The International Pediatric and Congenital Cardiac Code. Cardiol Young (2008) 2.10

Characterizing vulnerable plaque features with intravascular elastography. Circulation (2003) 2.07

Lineage and morphogenetic analysis of the cardiac valves. Circ Res (2004) 2.06

Is complete heart block after surgical closure of ventricular septum defects still an issue? Ann Thorac Surg (2006) 2.05

Stent fracture and restenosis in the drug-eluting stent era. Catheter Cardiovasc Interv (2004) 2.04

Depression is independently associated with 7-year mortality in patients treated with percutaneous coronary intervention: results from the RESEARCH registry. Int J Cardiol (2012) 2.04

Coronary stents: current status. J Am Coll Cardiol (2010) 2.01

Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol (2005) 2.00

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg (2012) 1.99

Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation (2005) 1.98

Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation (2010) 1.96

The morphological spectrum of ventricular noncompaction. Cardiol Young (2005) 1.96

Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. EuroIntervention (2009) 1.94

Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv (2012) 1.89

Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound. Circulation (2006) 1.89

Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv (2007) 1.88

Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study--TROFI trial. Eur Heart J (2013) 1.87

Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation (2008) 1.87

Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving system--a Bern-Rotterdam Study. Am Heart J (2010) 1.87

Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation (2004) 1.86

In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol (2005) 1.85

Disruption of planar cell polarity signaling results in congenital heart defects and cardiomyopathy attributable to early cardiomyocyte disorganization. Circ Res (2007) 1.85

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J (2012) 1.85

Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol (2008) 1.84

Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis (2011) 1.84

Multislice spiral computed tomography coronary angiography in patients with stable angina pectoris. J Am Coll Cardiol (2004) 1.84

The nomenclature, definition and classification of cardiac structures in the setting of heterotaxy. Cardiol Young (2007) 1.83

Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet (2012) 1.80

Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. J Am Coll Cardiol (2012) 1.80

Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2011) 1.80

Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention (2008) 1.80

An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J (2009) 1.79

Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J (2014) 1.78

The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol (2002) 1.78

Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv (2007) 1.77

Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac Surg (2011) 1.77

Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging (2012) 1.77

Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. J Am Coll Cardiol (2013) 1.76

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation (2010) 1.75

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg (2012) 1.74

Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J (2005) 1.74

Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: a randomized comparison. Am Heart J (2004) 1.74